Trending

market access

Windrose Consulting Group acquires Parioforma

Windrose Consulting Group acquires Parioforma

Windrose acquires Parioforma as part of growth strategy

X

Windrose Consulting Group acquires Parioforma

https://pharmaphorum.com/partner-content/windrose-consulting-group-acquires-parioforma/

Survey shows patients wait six times longer than EU neighbours for new drugs

Survey shows patients wait six times longer than EU neighbours for new drugs

Patients in some European countries are waiting up to six times longer for access to medicines than their neighbours,

X

Survey shows patients wait six times longer than EU neighbours for new drugs

https://pharmaphorum.com/news/survey-shows-patients-wait-six-times-longer-than-eu-neighbours-for-new-drugs/

Germany first in EU to get Novartis’ SMA gene therapy, costing almost 2m euros

Germany first in EU to get Novartis’ SMA gene therapy, costing almost 2m euros

Novartis is set to launch its one-off gene therapy Zolgensma for the ultra-rare muscle-wasting disease spinal muscular atrophy (SMA) in Germany at the start of July priced

X

Germany first in EU to get Novartis’ SMA gene therapy, costing almost 2m euros

https://pharmaphorum.com/news/novartis-eyes-smart-deal-for-sma-gene-therapy-in-uk/

NICE rejects Sanofi’s Cablivi for rare blood disorder TTP

NICE rejects Sanofi’s Cablivi for rare blood disorder TTP

NICE has rejected Sanofi’s Cablivi (caplacizumab) for the rare blood disorder thrombotic thrombocytic purpura (TTP) in first draft guidance. The cost-effectiveness body said

X

NICE rejects Sanofi’s Cablivi for rare blood disorder TTP

https://pharmaphorum.com/news/nice-rejects-sanofis-cablivi-for-rare-blood-disorder-ttp/

Jeff Anderson joins OPEN Health in European lead role

Jeff Anderson joins OPEN Health in European lead role

Jeff Anderson has joined OPEN Health as European Lead for its OPEN VIE and Pharmerit Europe practices. In

X

Jeff Anderson joins OPEN Health in European lead role

https://pharmaphorum.com/news/open-health-jeff-anderson-vie-pharmerit/

Market access in the time of COVID-19

Market access in the time of COVID-19

COVID-19 has left no part of life untouched, including health technology assessment (HTA) and other payer agency activities,

X

Market access in the time of COVID-19

https://deep-dive.pharmaphorum.com/magazine/market-access-2020/market-access-in-the-time-of-covid-19/

Gilead’s remdesivir could be $7.7bn blockbuster – analyst

Gilead’s remdesivir could be $7.7bn blockbuster – analyst

An influential analyst has upped his previously cautious assessment of the sales potential of Gilead’s COVID-19 drug remdesivir, saying

X

Gilead’s remdesivir could be $7.7bn blockbuster – analyst

https://pharmaphorum.com/news/gileads-remdesivir-could-be-7-7bn-blockbuster-analyst/

Deep Dive: Market Access – Breaking Barriers

Deep Dive: Market Access – Breaking Barriers

In this issue of Deep Dive we look at the changing landscape for pharma market access and start

X

Deep Dive: Market Access – Breaking Barriers

https://pharmaphorum.com/views-analysis-market-access/deep-dive-market-access/

NICE recommends Roche’s Tecentriq in ES-SCLC following price rethink

NICE recommends Roche’s Tecentriq in ES-SCLC following price rethink

NICE has said that Roche’s Tecentriq (atezolizumab) plus chemotherapy should be funded by the NHS as an option for untreated extensive-stage small-cell

X

NICE recommends Roche’s Tecentriq in ES-SCLC following price rethink

https://pharmaphorum.com/news/nice-recommends-roches-tecentriq-in-es-sclc-following-price-rethink/

1 2 3 4 5 >»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com